Skip to main content
Equibles
INMB logo

INMB · Inmune Bio, Inc. · Webcasts, Transcripts & Audio

Track INMB — free

Use INMB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INMB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.93 +0.00 (+0.00%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 6, 2026
Market Cap
$56.34M
Shares
27.75M
Volume · Oct 2 290.24K Avg daily vol (3M) 455.31K

Inmune Bio, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Inmune Bio, Inc. (INMB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $16,000 −$6.84M '22 Q2 22-08-04 ▲600% $98,000 −$7.72M '22 Q3 22-11-02 · $97,000 −$5.83M '22 Q4 23-03-03 ▼76.7% $38,000 −$6.54M '23 Q1 23-05-04 ▲187.5% $46,000 −$6.50M '23 Q2 23-08-08 ▼56.1% $43,000 −$8.56M '23 Q3 23-11-01 ▼71.1% $28,000 −$8.41M '23 Q4 24-03-29 ▼63.2% $14,000 −$11.03M '24 Q1 24-05-13 LATEST ▲257.1% $50,000 −$9.74M '25 Q1 25-05-08
Earnings call
FY26 · Q1
2026-03-31
Inmune Bio, Inc. (INMB) Q1 2026 Earnings Call Transcript
Positive tone CORDStrom regulatory filings and MAA submission RDEB program and branding XPro program and MINDFuL study
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-12-31
Inmune Bio, Inc. (INMB) Q4 2025 Earnings Call Transcript
Positive tone CORDStrom RDEB regulatory progress XPro Alzheimer's program INKmune prostate cancer program
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Inmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript
Confident tone CORDStrom RDEB regulatory progress Itch reduction / systemic benefit in RDEB INKmune prostate cancer Phase II
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Inmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript
Positive tone XPro Phase II MINDFuL trial in Alzheimer's CORDStrom for RDEB regulatory submissions Strategic partnership exploration
Diluted EPS
$-1.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Inmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript
Confident tone CORDstrom / RDEB program XPro market opportunity INKmune prostate cancer program
Revenue
$50,000
▲ 257.1% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Inmune Bio, Inc. (INMB) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-01
Inmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
Confident tone XPro ADO2 Phase II Alzheimer’s trial enrollment complete Ease of delivery / outpatient administration Treatment-resistant depression Phase II program
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-02
Inmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript
Confident tone INKmune NK cell oncology program XPro Phase II Alzheimer's trial (AD02) Treatment-resistant depression program
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Inmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript
Positive tone Alzheimer's Phase II AD02 trial enrollment and design Regulatory pathway and FDA interaction XPro long-term safety and patient experience
Revenue
$14,000
▼ 63.2% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-29
Inmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
Confident tone XPro Phase 2 Alzheimer's trial design and confidence INKmune prostate cancer trial Pipeline expansion beyond Alzheimer's
Revenue
$28,000*
▼ 71.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Inmune Bio, Inc. (INMB) Q3 2023 Earnings Call Transcript
Revenue
$43,000
▼ 56.1% YoY
Diluted EPS
$-0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Inmune Bio, Inc. (INMB) Q2 2023 Earnings Call Transcript
Revenue
$46,000
▲ 187.5% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Inmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript
Revenue
$38,000
▼ 76.7% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-03
Inmune Bio, Inc. (INMB) Q4 2022 Earnings Call Transcript
Revenue
$97,000*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Inmune Bio, Inc. (INMB) Q3 2022 Earnings Call Transcript
Revenue
$98,000
▲ 600% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Inmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript
Revenue
$16,000
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-06
Inmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript
Revenue
$163,000
▲ 3975% YoY
Diluted EPS
$-0.39
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-04
Inmune Bio, Inc. (INMB) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Inmune Bio, Inc. (INMB) Q3 2021 Earnings Call Transcript
Revenue
$14,000
Diluted EPS
$-0.55
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Inmune Bio, Inc. (INMB) Q2 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Inmune Bio, Inc. (INMB) Q1 2021 Earnings Call Transcript
Revenue
$4,000
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-05
Inmune Bio, Inc. (INMB) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Inmune Bio, Inc. (INMB) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Inmune Bio, Inc. (INMB) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-15
Inmune Bio, Inc. (INMB) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Inmune Bio, Inc. (INMB) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 webcasts
Key facts CIK 1711754 CUSIP 45782T105 13F (30d) 1 filings 1 filers Visit website Investor relations